Subject(s)
Glaucoma, Neovascular/surgery , Glaucoma, Open-Angle/surgery , Hyaluronic Acid/administration & dosage , Sclerostomy/methods , Trabeculectomy/methods , Aged , Chronic Disease , Female , Humans , Intraocular Pressure , Male , Postoperative Complications , Retrospective Studies , Surgical Flaps , Treatment Outcome , Visual AcuityABSTRACT
AIMS/BACKGROUND: To evaluate in a double-masked comparative, prospective, randomized multicenter trial the efficacy of lomefloxacin 0.3% eye drops twice daily and of tobramycin eye drops 4 times daily in patients with acute bacterial conjunctivitis. METHODS: Ninety-nine subjects were enrolled: 50 were treated with lomefloxacin 0.3% eye drops twice daily and 49 with tobramycin 0.3% eye drops 4 times daily. In all patients, conjunctival swabbing and assessment of objective signs and of subjective symptoms were performed. RESULTS: There was no statistical difference for any individual sign or symptom or for the sum score of either key or other signs and symptoms at any of the examination days. The sum score of both key and other signs and symptoms decreased in both groups at day 3-4 as compared to baseline values (p < 0.0001). The decrease in both these scores continued significantly from day 3-4 to day 7-8 (p < 0.05) and was similar in the two treatment groups (p > 0.4). The lowest resistance rate was seen in lomefloxacin (3.5%) and in neomycin (7.0%), while tobramycin showed resistance in 10 out of 88 resistance strains (11.4%). CONCLUSION: Both lomefloxacin 0.3% twice daily and tobramycin 0.3% administered 4 times daily were well tolerated and showed a high degree of clinical and microbiological efficacy in the treatment of acute bacterial conjunctivitis. Lomefloxacin caused less resistance than other antibiotics evaluated.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Anti-Infective Agents/therapeutic use , Conjunctivitis, Bacterial/drug therapy , Fluoroquinolones , Haemophilus Infections/drug therapy , Quinolones/therapeutic use , Staphylococcal Infections/drug therapy , Streptococcal Infections/drug therapy , Tobramycin/therapeutic use , Acute Disease , Adolescent , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/administration & dosage , Anti-Infective Agents/administration & dosage , Bacteria/drug effects , Bacteria/growth & development , Bacteria/isolation & purification , Child , Colony Count, Microbial , Conjunctiva/microbiology , Conjunctivitis, Bacterial/microbiology , Double-Blind Method , Female , Follow-Up Studies , Haemophilus Infections/microbiology , Humans , Male , Middle Aged , Ophthalmic Solutions , Prospective Studies , Quinolones/administration & dosage , Staphylococcal Infections/microbiology , Streptococcal Infections/microbiology , Tobramycin/administration & dosage , Treatment OutcomeABSTRACT
In the surgical treatment of autoimmune myasthenia, complete thymectomy is considered indispensable to ensure maximum clinical results. From May 1995 through June 1997, we carried out video-assisted extended thymectomy via sole left access in 16 patients. There were no deaths and no major complications. At the intermediate-term follow-up, remission and improvement rates were 19% and 56% respectively. These results were similar to those achieved on the last 16 patients who had extended thymectomy via median sternotomy. We believe that the advantages of the video-assisted approach render it a reliable option for the surgical management of autoimmune myasthenia.
